Latest Regulatory Incentives News

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.